WuXi Advanced Therapies, a global contract development and manufacturing organization (CDMO) offering end-to-end contract services for the advance therapies industry, has expanded its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.
 
This service will provide advanced therapy companies worldwide with an integrated platform for AAV vector production that includes: in-stock raw materials with established batch records; regulatory and technical expertise; process and analytical development; full in-process and release testing; robust quality control and quality assurance oversight; and facilities that offer the capacity and flexibility to meet client timeline needs with enhanced scalability that range up to 1000L.
 
“We are excited to bring a world-class AAV Suspension Platform to our customers,” said Felix Hsu, senior vice president and global head, WuXi AppTec Advanced Therapies. “We will continue to develop platforms that help our customers bring their innovative therapies to patients and to market with even greater predictability and speed.”